(Q38194162)

30 August 2017

1 reference

title

Analysis of patents on anti-gout therapies issued in China (English)

1 reference

30 August 2017

0 references

Hong-Yu Yuan

1

1 reference

30 August 2017

Xue-Hui Zhang

2

1 reference

30 August 2017

Xiao-Lan Zhang

3

1 reference

30 August 2017

Ji-Fu Wei

4

1 reference

30 August 2017

Ling Meng

5

1 reference

30 August 2017

language of work or name

English

0 references

publication date

7 March 2014

1 reference

Expert Opinion on Therapeutic Patents

30 August 2017

1 reference

30 August 2017

24

1 reference

30 August 2017

5

1 reference

30 August 2017

555-572

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

30 August 2017

1 reference

Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Dietary risk factors for rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Contemporary epidemiology of gout in the UK general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Seasonality and trends in the incidence and prevalence of gout in England and Wales 1994-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Xanthine oxidase inhibitors: a patent survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Gout therapeutics: new drugs for an old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Latest evidence on gout management: what the clinician needs to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Pathway analysis of genome-wide association studies on uric acid concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Hydrophilic ester-bearing chlorogenic acid binds to a novel domain to inhibit xanthine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Hydroxychavicol: a potent xanthine oxidase inhibitor obtained from the leaves of betel, Piper betle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Effects of Biota orientalis extract and its flavonoid constituents, quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Insights into the inhibition of xanthine oxidase by curcumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Synthesis of some 5-phenylisoxazole-3-carboxylic acid derivatives as potent xanthine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Developing potent human uric acid transporter 1 (hURAT1) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

A colorimetric 96-well microtiter plate assay for the determination of urate oxidase activity and its kinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Transthyretin-related proteins function to facilitate the hydrolysis of 5-hydroxyisourate, the end product of the uricase reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Loss of urate oxidase activity in hominoids and its evolutionary implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Urate oxidase in primate phylogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Uricase and other novel agents for the management of patients with treatment-failure gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

A pilot study of IL-1 inhibition by anakinra in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Lonicera hypoglauca inhibits xanthine oxidase and reduces serum uric acid in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

A two-stage approach to the treatment of hyperuricemia in gout: The “dirty dish” hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

Intellectual property protection in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.895325

10.1517/13543776.2014.895325

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference